Yannick Guilloux
Overview
Explore the profile of Yannick Guilloux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Persello A, Dupas T, Vergnaud A, Blangy-Letheule A, Aillerie V, Erraud A, et al.
Heliyon
. 2024 May;
10(9):e30526.
PMID: 38737268
Background: Dietary intake and metabolism variations are associated with molecular changes and more particularly in the transcriptome. O-GlcNAcylation is a post-translational modification added and removed respectively by OGT and OGA....
2.
Roy C, Avril S, Legendre C, Lelievre B, Vellenriter H, Boni S, et al.
BMC Cancer
. 2022 Aug;
22(1):843.
PMID: 35918659
Background: Glioblastoma (GB) is the most common and most aggressive malignant brain tumor. In understanding its resistance to conventional treatments, iron metabolism and related pathways may represent a novel avenue....
3.
Perrin J, Capitao M, Allard M, Chouin N, Gouard S, Marionneau-Lambot S, et al.
Int J Radiat Oncol Biol Phys
. 2021 Oct;
112(3):790-801.
PMID: 34699930
Purpose: The tumor microenvironment (TME) can severely impair immunotherapy efficacy by repressing the immune system. In a multiple myeloma (MM) murine model, we investigated the impact of targeted alpha particle...
4.
Capitao M, Perrin J, Simon S, Gouard S, Chouin N, Bruchertseifer F, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809167
PD-L1 (programmed death-ligand 1, B7-H1, CD274), the ligand for PD-1 inhibitory receptor, is expressed on various tumors, and its expression is correlated with a poor prognosis in melanoma. Anti-PD-L1 mAbs...
5.
Perrin J, Capitao M, Mougin-Degraef M, Guerard F, Faivre-Chauvet A, Rbah-Vidal L, et al.
Front Med (Lausanne)
. 2020 Mar;
7:34.
PMID: 32118018
The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new...
6.
Menager J, Gorin J, Fichou N, Gouard S, Morgenstern A, Bruchertseifer F, et al.
Med Sci (Paris)
. 2016 May;
32(4):362-9.
PMID: 27137693
Alpha-radioimmunotherapy (α-RIT) is a targeted anti-tumor therapy using usually a monoclonal antibody specific for a tumor antigen that is coupled to an α-particle emitter. α-emitters represent an ideal tool to...
7.
Gorin J, Gouard S, Menager J, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, et al.
Front Med (Lausanne)
. 2015 Nov;
2:74.
PMID: 26539436
Objectives: Radiation emitted by the radionuclides in radioimmunotherapy (RIT) approaches induce direct killing of the targeted cells as well as indirect killing through the bystander effect. Our research group is...
8.
Menager J, Gorin J, Maurel C, Drujont L, Gouard S, Louvet C, et al.
PLoS One
. 2015 Jun;
10(6):e0130249.
PMID: 26098691
Ionizing radiation induces direct and indirect killing of cancer cells and for long has been considered as immunosuppressive. However, this concept has evolved over the past few years with the...
9.
Gorin J, Guilloux Y, Morgenstern A, Cherel M, Davodeau F, Gaschet J
Oncoimmunology
. 2015 May;
3(9):e954925.
PMID: 25941605
Radioimmunotherapy aims to deliver radiation directly to cancer cells by means of a tumor specific vector coupled to a radionuclide. Alpha radionuclides are very potent agents to treat disseminated cancer...
10.
Gorin J, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al.
Neoplasia
. 2014 May;
16(4):319-28.
PMID: 24862758
Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for...